Curcumin-loaded nanostructured lipid carriers (NLCs) for nasal administration: design, characterization, and in vivo study

Drug Delivery

Volumn 23, Issue 4, 2016, Pages 1326-1334

  Madane, Rohini G ^a   Mahajan, Hitendra S ^a  

^a R C PATEL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH   (India)

Author keywords

Curcumin; nanostructured lipid carrier; nasal drug delivery

Indexed keywords

CURCUMIN; LIPID; NANOCARRIER; NANOSTRUCTURED LIPID CARRIER; UNCLASSIFIED DRUG; DRUG CARRIER; NANOMATERIAL; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; ASTROCYTOMA; CONTROLLED STUDY; CYTOTOXICITY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG PENETRATION; DRUG RELEASE; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VIVO STUDY; LOADING DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PARTICLE SIZE; PHOTON CORRELATION SPECTROSCOPY; PRIORITY JOURNAL; RAT; SUSTAINED DRUG RELEASE; TIME TO MAXIMUM PLASMA CONCENTRATION; ZETA POTENTIAL; BLOOD BRAIN BARRIER; CHEMISTRY; INTRANASAL DRUG ADMINISTRATION; METABOLISM; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ADMINISTRATION, INTRANASAL; ASTROCYTOMA; BLOOD-BRAIN BARRIER; CELL LINE, TUMOR; CURCUMIN; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; LIPIDS; NANOPARTICLES; NANOSTRUCTURES; TISSUE DISTRIBUTION;

EID: 84975223468     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2014.975382     Document Type: Article

References (26)

1. B.B.Aggarwal, A.Kumar, A.C.Bharti. (2003). Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 23:363–98
2. P.Anand, A.B.Kunnumakkara, R.A.Newman, B.B.Aggarwal. (2007). Bioavailability of curcumin: problems and promises. Mol Pharm 4:807–18
3. J.Araújo, E.Gonzalez-Mira, M.A.Egea,. (2010). Optimization and physicochemical characterization of a triamcinolone acetonide-loaded NLC for ocular antiangiogenic applications. Int J Pharm 393:167–75
4. J.L.Arbiser, N.Klauber, R.Rohan. (1998). Curcumin is an in vivo inhibitor of angiogenesis. Mol Med 4:376–83
5. L.Battaglia, M.Gallarate. (2012). Lipid nanoparticles: state of the art, new preparation methods and challenges in drug delivery. Expert Opin Drug Deliv 9:497–508
6. S.V.Bava, V.T.Puliappadamba, A.Deepti,. (2005). Sensitization of taxol-induced apoptosis by curcumin involves down-regulation of nuclear factor-nB and the serine/threonine kinase Akt and is independent of tubulin polymerization. J Biol Chem 280:6301–8
7. M.M.Chan, D.Fong, K.J.Soprano,. (2003). Inhibition of growth and sensitization to cisplatin-mediated killing of ovarian cancer cells by polyphenolic chemopreventive agent. J Cell Physiol 194:63–70
8. H.H.S.Chow, Z.Chen, G.T.Matsuura. (1999). Direct transport of cocaine from the nasal cavity to the brain following intranasal cocaine administration in rats. J Pharm Sci 88:754–8
9. F.Feng, D.Zheng, D.Zhang,. (2011). Preparation, characterization and biodistribution of nanostructured lipid carriers for parenteral delivery of bifendate. J Microencapsul 28:280–5
10. C.W.How, R.Abdullah, R.Abbasalipourkabir. (2011). Physicochemical properties of nanostructured lipid carriers as colloidal carrier system stabilized with polysorbate 20 and polysorbate 80. Afr J Biotechnol 10:1684–9
11. X.G.Jiang, J.B.Cui, X.L.Fang,. (1995). Toxicity of drugs on nasal mucocilia and the method of its evaluation. Acta Pharmacol Sin 30:848–53
12. M.D.Joshi, R.H.Müller. (2009). Lipid nanoparticles for parenteral delivery of actives. Eur J Pharm Biopharm 71:161–72
13. W.M.Kakkar, K.Schwabe, R.H.Müller, C.M.Keck. (2013). Preservation of nanostructured lipid carriers (NLC). Eur J Pharm Biopharm 76:56–67
14. C.Li. (2002). Poly (l-glutamic acid)–anticancer drug conjugates. Adv Drug Deliv Rev 54:695–713
15. L.Li, F.S.Braiteh, R.Kurzrock. (2005). Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer 104:1322–31
16. C.H.Liu, C.T.Wu. (2010). Optimization of nanostructured lipid carriers for lutein. Colloids Surf A: Physicochem Eng Asp 353:149–56
17. D.Liu, Z.Liu, L.Wang,. (2011). Nanostructured lipid carriers as novel carrier for parenteral delivery of docetaxel. Colloids Surf B Biointerfaces 85:262–9
18. Z.Liu, X.Zhang, H.Wu,. (2011). Preparation and evaluation of solid lipid nanoparticles of baicalin for ocular drug delivery system in vitro and in vivo. Drug Dev Ind Pharm 37:475–81
19. A.Mistry, S.Stolnik, L.Illum. (2009). Nanoparticles for direct nose to brain delivery of drugs. Int J Pharm 379:146–57
20. L.Montenegro, A.Campisi, M.G.Sarpietro,. (2011). In vitro evaluation of idebenone-loaded solid lipid nanoparticles for drug delivery to the brain. Drug Dev Ind Pharm 37:737–46
21. R.H.Müller, M.Radtke, S.A.Wissing. (2002). Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm 242:121–8
22. A.M.Nyström, B.Fadeel. (2012). Safety assessment of nanomaterials: implications for nanomedicine. J Control Release 16:403–8
23. W.M.Obeidat. (2012). Investigation of temperature-induced physical instability of preserved coenzyme Q10-loaded (NLC): a comparative study at different temperatures. Afr J Pharm Pharmacol 6:2413–23
24. Y.B.Pawar, H.Purohit, G.R.Valicherla,. (2012). Novel lipid based oral formulation of curcumin: development and optimization by design of experiments approach. IntJ Pharm 436:617–23
25. X.Zhang, J.Liu, H.Qiao,. (2010). Formulation and optimization of dihydroartemisinin nanostructured lipid carrier using response surface methodology. Powder Technol 197:120–8
26. L.Zhao, S.Feng. (2010). Enhanced oral bioavailability of paclitaxel formulated in vitamin E-TPGS emulsified nanoparticles of biodegradable polymers: in vitro and in vivo studies. J Pharm Sci 99:3552–60